Abstract
SRC is a tyrosine kinase that plays a role in oncogenic, invasive and bone-metastatic processes. It has therefore been prioritized as a candidate therapeutic target in patients with solid tumors. Several SRC inhibitors are now in development, of which dasatinib has been most explored. Preclinical studies in a wide variety of solid tumor cell lines, including prostate, breast and glioma, have shown that that dasatinib acts as a cytostatic agent, inhibiting the processes of cell proliferation, invasion and metastasis. Dasatinib also inhibits the activity of osteoclasts, which have a major role in the development of metastatic bone lesions. Dasatinib has additive or synergistic activity in combination with a number of other agents, including cytotoxic agents and targeted therapies, providing a rationale for combination treatment in a clinical setting. Emerging clinical data with dasatinib support experimental observations, with preliminary phase 1 and 2 data demonstrating activity, both as a single agent and as combination therapy, in a range of solid tumors. Future clinical trials will further assess the clinical value of SRC inhibition with dasatinib.
Original language | English (US) |
---|---|
Pages (from-to) | 492-500 |
Number of pages | 9 |
Journal | Cancer treatment reviews |
Volume | 36 |
Issue number | 6 |
DOIs | |
State | Published - Oct 2010 |
Keywords
- Bone metastases
- Dasatinib
- Phase 1 clinical trials
- Phase 2 clinical trials
- Preclinical
- SRC kinase
- Solid tumors
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging